INTRODUCTION
Over ninety percent of the world's HIV-infected pregnant women live in sub-Saharan Africa and, with recent progress in preventing mother-to-child HIV transmission the vast majority of infants born to these women are uninfected. (1) There is now increasing evidence, however, that HIV-exposed, uninfected (HEU) infants are experiencing increased rates of morbidity and mortality compared to children born to HIV-uninfected mothers, (2, 3) although the reasons for this remain unknown.
One hypothesis is that intrauterine differences may adversely affect the HIV-exposed 
METHODS
Study population. This study was conducted at Kalafong Hospital in Tshwane, South Africa between September 2010 and May 2011, and was approved by the institutional review boards of the University of Pretoria and Yale University. After giving consent, ninety-one women were initially enrolled. IRB approval was obtained to have research assistants attend the labor ward and invite women who were late in pregnancy or early labor to participate. Women older than 15 year with uncomplicated, singleton pregnancies were eligible to participate if they resided in the greater Pretoria area and intended to remain in the area. The HIV-infected group included only those who were diagnosed as positive for the first time in the current pregnancy.
HIV-uninfected women were required to have evidence of a negative test completed during the pregnancy. Women with a history of psychiatric illness and those who were likely to move out of the area were not eligible.
After enrollment, all women completed short interviews to obtain socio-demographic and pregnancy-related information. HIV-infected women provided information regarding illness history, antiretroviral treatment and adherence. Additional data relating to pregnancy, delivery and CD4 count were abstracted from medical records. Previously established methods were used to establish accuracy of gestational age. (14) According to the 2010-2011 South Africa PMTCT guidelines(15), women with CD4 <350 received combination antiretroviral therapy (tenofovir (TDF), nevirapine (NVP), and lamivudine or emtracitabine (FTC)) during pregnancy and those with CD4 >350 received antenatal zidovudine (AZT), and intrapartum single-dose NVP and AZT. Data on duration of ARV treatment and responses to treatment were not available. All infants were confirmed uninfected by HIV PCR testing done at local clinics at 6 weeks of age. Women were invited to return with their children for follow-up interviews conducted at 3 months of age. Four children were lost to follow-up and therefore removed from subsequent analyses, leaving 87 women and infants in the final analysis.
Biological specimens. Maternal venous blood samples obtained at enrollment were sent to the clinical laboratory for hemoglobin, hematocrit, white blood cell (WBC) and platelet counts. CB was collected prior to expulsion of the placenta using a standardized protocol (16) and blood was distributed between serum and citrated plasma tubes. The technique of direct umbilical vein puncture precluded the inadvertent contamination of the sample with maternal blood. This was confirmed by lack of haptoglobin immunoreactivity in CB and also higher ferritin levels in CB compared to maternal blood. Samples were centrifuged for 10 minutes (1,000g, 4ºC) and subsequently stored at -80ºC.
Indices of iron status. Automated analyzers were used for measurement of iron indices including: iron (colorimetric assay, P800/Cobas modular analyzer, Roche), ferritin (chemiluminescent assay, E170 modular analyzer, Roche) and transferrin (immunoturbidimetric assay, P800 analyzer, Roche). Total iron binding capacity (TIBC, calculated) and percent transferrin saturation (calculated) were determined in both maternal and cord blood serum while sTfR (immunoturbidimetric assay, Integra400 analyzer, Roche) and sTfR/F index (calculated) were determined only in CB serum. 
Comparisons among linked maternal and CB samples were by 2-way repeated measures (ANOVA) after logarithmic transformation. Correlation analyses were performed using Spearman's rank order correlation.
RESULTS
Ninety-one women were initially enrolled but 4 were lost to follow-up and thus excluded from subsequent analyses. Our final analysis included 87 women: 42 were HIV-uninfected and 45 HIV-infected, of which 51% (23/45) were on HAART therapy. CD4 counts were available for 41/45 HIV-infected women. Among these women 11 (27%) had CD4 counts <200, 15 (37%) had CD4 counts 200-349, and 15 (37%) had CD4 counts ≥350. The mean age of HIV-infected women was slightly older (28.0 versus 25.0, P=0.045) and there were also fewer primigravidas (18% versus 43%, P=0.024). There were no significant differences between groups with respect to labor/delivery and neonatal characteristics.
Nearly all pregnancies were full term in both groups and birth weights were all >2000 grams, with 51% >3000 grams. Both groups had high rates of Cesarean section (58% HIVinfected vs. 52% HIV-uninfected). Fewer women in the HIV-infected group had premature rupture of membranes (2% vs. 12%), although not statistically significant. More than half of all women in each group were treated with antibiotics during or after delivery (64% vs. 53%). but there were no differences in maternal iron, TIBC, or transferrin levels. For both HIVinfected and uninfected groups, mean CB ferritin was more than four times higher than respective maternal ferritin levels. Ferritin levels were also higher in CB of HEU infants when compared to HIV-uninfected CB (184.0 vs. 136.0 ng/mL, P=0.044); however, there was no elevation in CB iron or transferrin receptor levels. In the HIV-infected group, there were no differences in either maternal ferritin levels (P=0.69) or cord blood ferritin (P=0.73) for those receiving HAART and those not receiving HAART. It is notable that there were no significant differences between groups in IL-6 or haptoglobin switch-on status, and measures of oxidative stress (TRAP & sRAGE). CRP was slightly higher in the HIV-uninfected group.
Subsequent analyses showed no significant correlation between maternal and CB ferritin levels (r=0.24, P=0.11). Furthermore, there was no correlation between ferritin and IL-6, CRP or TRAP in CB. However, as shown in the figure, a significant inverse correlation between sRAGE and CB sTfR/F index (r=-0.427, P=0.004) was found in HIV-infected but not in HIV-uninfected subjects (r=-0.132, P=0.403) (not shown). 
DISCUSSION
This study demonstrates that maternal HIV infection induces a state of fetal hyperferritinemia, which is unrelated to maternal ferritin level and does not appear secondary to fetal pro-inflammatory state. We also found elevated maternal ferritin levels among HIVinfected women, which has been previously described (6) and has been shown to inversely correlate with CD4 levels, and is an indicator of poorer prognosis and increased mortality. (19) In HIV-uninfected women, elevated maternal ferritin has been associated with higher rates of pregnancy complications such as gestational diabetes, intra-uterine growth retardation (IUGR), and neonatal sepsis. (20) We found no association between CB ferritin and maternal ferritin levels in HIV-uninfected mothers, which suggests independent sources of hyperferritinemia and is consistent with previous studies. (21) In South Africa, all mothers routinely receive iron therapy during pregnancy; however, adherence to this was not assessed.
Although the mechanism of elevated ferritin in cord blood of HEU infants remains to be elucidated, we can make some inferences. Ferritin normally reflects the storage iron compartment and sTfR reflects the functional iron compartment, (8) A potentially important clue may result from the inverse correlation between CB sRAGE and sTfR/F index. sRAGE plays a role in inflammation and oxidative stress-induced tissue injury.(10) Low cord blood sRAGE levels have been reported in premature newborns exposed to intra-amniotic inflammation and recently in IUGR independent of fetal inflammation. (22) It is possible that in this cohort, ferritin is being produced in the placenta in response to a state of oxidative stress, resulting in excess RAGE ligand and leading to consumption of sRAGE.
Unaffected CB TRAP levels are more consistent with a state of chronic rather than acute oxidative stress. The CB ferritin levels elevated beyond maternal levels support a fetal or placental source of ferritin that is independently modulated by maternal HIV infection. Although elevated ferritin has been associated with a number of adverse effects in chronic inflammatory conditions and malignancy, it ultimately remains unknown whether hyperferritinemia in CB has long-term deleterious effects on postnatal development. As ferritin emerges to have bioactivities independent of its iron storage function such as angiogenesis regulation, (23) further studies investigating the mechanism and kinetics of hyperferritinemia in HEU infants beyond birth are warranted.
The high rates of antibiotic administration in the study are likely a reflection of local practice. There is no routine screening for B-hemolytic streptococci during pregnancy and all women undergoing cesarean sections receive antibiotics. Indications for giving antibiotics were the same for all mothers and there was no significant difference in numbers between groups (64% HIV-infected vs. 53% HIV-uninfected).
In summary, this study demonstrated elevated ferritin levels among HIV-infected pregnant women, a finding that has previously been associated with a poorer prognosis in nonpregnant, HIV-infected individuals. Additionally, we report for the first time that ferritin is significantly elevated in CB of HEU infants compared to those who are not HIV-exposed. The finding that markers of inflammation (CRP, IL-6) were unchanged suggests that the increase in CB ferritin is unlikely caused by inflammation. The inverse relationship between sTfR/F index and sRAGE in CB suggests that oxidative stress may play a role in modulating ferritin levels.
Further research is necessary to explain these findings and to determine whether this observation might contribute to adverse outcomes among HEU infants.
